Large-scale testing (Phase 3)Study completedNCT01691248
What this trial is testing
Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)
Who this might be right for
Clostridium Difficile-Associated Diarrhea (CDAD)
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 611